Registration Number
0224U002364,
(0123U104369)
, R & D reports
Title
Cytokine-induced killer T cells and bacterial lectins as new biotherapy for breast cancer: an in vitro study
popup.stage_title
Розробити платформу для in vitro тестування CIK у поєднанні з лектином B. subtilis ІМВ В-7724 на моделі клітинних ліній раку молочної залози з різним ступенем злоякісності та чутливості до хіміопрепаратів.
Head
Karaman Olha M., Кандидат біологічних наук
Registration Date
12-02-2024
Organization
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine
popup.description1
Фундаментальні наукові дослідження з найважливіших проблем розвитку науково-технічного, соціально-економічного, суспільно-політичного, людського потенціалу.
popup.description2
The production protocol for obtaining a clinically significant dose of CIК with high functional activity was optimized. A method of CIK viability monitoring was developed by assessing their metabolic activity due to glucose consumption. The obtained cellular product was characterized by a high content of functionally active CD3+CD56+killer lymphocytes (cytotoxic activity) against tumor cells. Lectin B. subtilis IMB B-7724 doesn't cause a toxic effect on human T-lymphocytes and can act as a mitogen. It was first discovered that lectin in human ВС cells activates the apoptotic program in a Caspase 3/7-dependent way. The cytotoxic effect of CIК against MCF-7 and MDA-MB-231 BC cells can be enhanced by incubation with lectin B. subtilis IMВ B-7724. In a 3D model of BC cell culture, it was proven that lectin does not affect the size of spheroids, but prevents the spread of tumor cells. The obtained data show the promise of the combined use of bacterial lectins and cytokine-induced killer T-cells as a new strategy for cancer biotherapy.
Product Description
popup.authors
Voeykova Iryna M.
Lykhova Oleksandra O.
Cheremshenko Nadiia L.
Chekhun Vasyl F.
popup.nrat_date
2024-02-12
